Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Broadly as expected at the headline level

Macquarie Group
3:27pm
May 11, 2025
MQG’s FY25 NPAT (A$3.7bn) was +1% above Factset consensus (A$3.7bn). Overall, we saw this result as largely as expected, with the positive share price reaction (+3%) likely reflecting a more stable result outcome versus MQG’s recent history of earnings disappointments. We downgrade our MQG FY26F/FY27F EPS by 2%-3%. Our PT rises to A$223 with our earnings changes offset by a valuation roll-forward. MQG is a quality franchise, and with a recent pull back in the share price occurring linked to macro and global trade factors, we see upside and move to an ADD (from Hold) recommendation.

A stable performer despite the volatile macro

REA Group
3:27pm
May 11, 2025
REA’s 3Q25 performance was largely driven by a strong yield growth (+15%) outcome in the resilient domestic residential business. REA India’s topline growth was also a key highlight, being up 28% on pcp despite the market remaining competitive. Group revenue and EBITDA (excl. associates) were up 12% in the quarter vs the pcp. We make only minor adjustments to our FY25-FY27 EPS forecasts (-0.4%), largely related to our 2H25 volume growth assumption given REA’s FY25 growth guidance. Our price target increases slightly to A$250 (from A$248) on the timing impacts of our DCF-derived valuation. Hold maintained.

Cost control

Civmec
3:27pm
May 9, 2025
3Q revenue was softer than expectations, though costs were well managed, which saw the company’s EBITDA margin rise to 12.1% from 10.5% at 1H. The company has given soft guidance for 4Q to be similar to 3Q which implies FY25 revenue of $818m and NPAT of $42.5m. The order book has risen for the first time in some time to >$760m ($633m at 1H), which ordinarily signals a return to growth. We trim our FY25 EBITDA and NPAT forecasts by 3% and 5% respectively. For FY26-27, we reduce our EBITDA forecasts by 3-4% and NPAT by 4-7%. The stock is cheap (~12x FY25 PE) and is yielding a 6% dividend (fully-franked) but we see a lack of near-term catalysts outside of the Landing Craft Heavy (LCH) naval shipbuilding contract, for which the timing is uncertain. We retain our Hold recommendation, though we see significant long-term potential in the business, particularly given the defence angle.

On wood

Avita Medical
3:27pm
May 9, 2025
AVH produced an optically difficult quarter. Strong progress year-on-year (sales +67%), but little to show on a consecutive quarterly basis (sales flat) on the key market focus metrics of sales and cash burn (which increased). Granted, it’s a seasonally weaker sales and higher expense period, but with cash balance versus burn getting tight, it needed a better print to address cash concerns. However, cost-cutting initiatives and commercial launches are expected to hit from 2Q and expected to see a material change and on its way to cashflow breakeven in 2H25 and profitability on a run-rate basis by 4Q25. Based on the new cost savings, RECELL growth (including mini), and new products, we still view guidance as achievable but also have to assume at this point a capital injection is required. Given the increased risks, the market appears to have reservations about their ability to deliver on guidance. Our valuation falls to A$3.76 (from A$4.36) and we move AVH to a Speculative Buy recommendation (from Add) given the increased balance sheet risk.

1Q25 result: Earnings to scale from here

Light & Wonder
3:27pm
May 9, 2025
Light & Wonder’s (NDAQ/ASX: LNW) 1Q25 result came in below both our forecasts and market expectations, although managed to deliver the double digit earnings growth it guided to on the last quarterly call, with Adj-EBITDA growing 11% yoy to US$311m, while margins improved 300bps following improved mix. Importantly, the company outlined the building blocks underpinning its outlook, despite the noise around the macro and Trump-era tariffs. We view the recent sell-off as a compelling entry point ahead of this month’s Investor Day in New York, particularly given the valuation support at current levels (FY26F PER ~13x). We continue to prefer LNW over peer Aristocrat (ALL) on valuation grounds. Our FY25-26F earnings estimates are largely unchanged. Retain Add rating, A$193 target price.

Sales continue to build

Polynovo
3:27pm
May 9, 2025
PNV has provided a trading update for the 9 months ended March 2025, noting sales growth of 31.1%. We are confident our FY25 forecast can be achieved and this rate of growth will continue in 4Q25. PNV has made progress on the regulatory front with a number of approvals achieved during the quarter and importantly the data for the full thickness burns trial is shortly to be locked and then submitted to the FDA to commence the approval process (expected to take six months). A search for a new CEO is underway and we view this as an important step for leadership stability. Given the positive sales momentum we have upgraded our recommendation to Speculative Buy (from Hold). Our new target price is A$1.69 (was $1.37).

Flat underlying; switch to conserving/growing capital

ANZ Banking Group
3:27pm
May 8, 2025
Strong 1H25 headline earnings growth beat consensus but was flat excluding the Suncorp Bank acquisition. We make material downgrades to forecast cash earnings (which were previously more bullish than consensus). We see approaching capital tightness in the CET1 ratio. ANZ is seeking to retain (slow and extend the existing buyback, held the DPS flat) and issue (DRP) capital. Hence, the outlook for ROE and per share metrics is poorer than previously. 12 month target price downgraded c.8% to $24.51/sh. Cash yield c.5.6%.

Mix and margin benefits = strong growth

Orica
3:27pm
May 8, 2025
ORI’s 1H25 result was strong and beat consensus EBIT and NPAT by 5.4% and 9.7% respectively. Underlying EBIT, NPAT, EPS and DPS all increased 34%/40%/33%/32% on the pcp. ORI is on track to report strong growth for the full year and has also provided positive outlook commentary for FY26. We have made minor upgrades to our forecasts which were previously above consensus estimates. With leverage to attractive industry fundamentals, market leading positions, strong earnings growth, proven management team and strong balance sheet, we think ORI’s trading multiples are undemanding and reiterate our Add rating.

Diversity kicks in

Super Retail Group
3:27pm
May 8, 2025
SUL’s trading update was slightly softer, but generally better-than-feared as strength in BCF/rebel offset weaker contributions from SCA/Macpac. We are encouraged by the evidence of stability within SCA through April, sustained sales strength of BCF (+8.3% in FY25); ongoing positive momentum within rebel; and continued investment through the cycle (distribution, store network, systems). We view the LT investment case intact and discount to peers unwarranted. Add.

Well-funded to advance programs

Syntara
3:27pm
May 8, 2025
Quarterly operational cash use of A$3.5m declined 35% on pcp, with staff costs down 26%, but R&D up 9%. Lead drug candidate SNT-5505 targeting bone cancer myelofibrosis is expected to report Phase 2 interim data at a medical conference in Jun-25. The skin scarring program has shown biological and structural normalisation of established scars, similar to normal, uninjured skin for SNT-6302, while next-generation topical SNT-9465 will enter Phase 1a/b testing this quarter. Phase 2a recruitment for SNT-4728 in Isolated REM Sleep Behaviour Disorder (iRBD) should accelerate with the opening of a UK site, with full enrollment expected by YE25 subsequent to data 1H26. The company sits on A$18m in cash, giving more than 5 quarters of runway at current burn.

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more